Clinical trial
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
NCT00002775 · Herbert Irving Comprehensive Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00002775 |
|---|---|
| Title | Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer |
| Official title | PHASE I/II STUDY OF DOCETAXEL (TAXOTERE) AND ESTRAMUSTINE COMBINATION CHEMOTHERAPY IN PATIENTS WITH PROSTATE CANCER |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, estramustine phosphate sodium |
| Enrollment | 37 |
| Start date | Feb 1, 1998 |
| First posted | Sep 2, 2004 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: